Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Hemispherx Biopharma Inc (NYSE American:HEB)

0.31
Delayed Data
As of Dec 14
 -0.004 / -1.27%
Today’s Change
0.30
Today|||52-Week Range
0.93
-55.06%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$9.9M

Company Description

Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Contact Information

Hemispherx Biopharma, Inc.
One Penn Center
Philadelphia Pennsylvania 19103
P:(215) 988-0080
Investor Relations:

Employees

Shareholders

Other institutional2.75%
Individual stakeholders2.08%
Mutual fund holders1.30%

Top Executives

Thomas Kenwood EquelsExecutive Vice Chairman, President & CEO
Wayne S. SpringateSenior Vice President-Operations
Adam PascaleChief Financial & Accounting Officer
David R. StrayerChief Scientific Officer & Medical Director
Peter W. RodinoSecretary & General Counsel